亿万富翁生物科技大亨努巴尔·阿费扬呼吁紧急监管科技公司正在销售的人工智能代理，警告说等待灾难发生将重蹈制药业过去的错误。
Billionaire biotech mogul Noubar Afeyan has called for urgent regulation of artificial intelligence agents that tech firms are selling, warning that waiting for a disaster risks repeating the past mistakes of the drug industry.
他将此与20世纪50年代和60年代的沙利度胺悲剧相提并论——当时孕妇服用该药导致胎儿畸形。莫德纳公司创始人阿费扬认为，寻求从人工智能代理中获利的公司必须在商业化推出之前承担其安全责任。
Drawing a parallel with the thalidomide tragedy in the 1950s and 60s, where the drug taken by pregnant women led to birth defects, the founder of Moderna Inc. argued that companies seeking to profit from AI agents must take responsibility of their safety before launching them commercially.
“我认为我们应该做的是，仔细思考如何监管那些正在商业化、并正在超出某些人可能希望在内部进行的范围之外传播的代理，”64岁的阿费扬周二在新德里的彭博新经济论坛上表示。
“I believe what we should do is to think carefully about regulating agents that are being commercialized and that are being transmitted outside the boundaries of what somebody may want to do in house,” Afeyan, 64, said at the Bloomberg New Economy Forum in New Delhi Tuesday.
阿费扬加入了越来越多的科技领袖和研究人员的行列，包括OpenAI首席执行官山姆·奥尔特曼和Anthropic PBC首席执行官达里奥·阿莫代伊，他们呼吁在人工智能变得更强大和更自主之际加强防护措施。奥尔特曼和阿莫代伊上个月曾在联合国安理会的一次聚焦人工智能潜在存在性风险的亮相中，敦促世界领导人共同应对人工智能议题——这一立场与美国总统唐纳德·特朗普的亲科技观点相矛盾。
Afeyan joins a growing cohort of technology leaders and researchers including OpenAI Chief Executive Officer Sam Altman and Anthropic PBC CEO Dario Amodei, in calling for stronger safeguards as AI grows more powerful and autonomous. Altman and Amodei last month urged world leaders to work together on AI during an appearance before the United Nations Security Council that focused on the technology’s potential existential risks, a stance that contradicts with US President Donald Trump’s pro-technology views.
阿费扬表示，监管应针对正在开发人工智能代理的公司，而非大型语言模型。“在我看来，LLMs是能力。代理是 intentionality（意图性）。”专家警告称，一批新兴的人工智能代理——能够自我指导并在无人类指令下运作——虽然可能加速药物发现和科学研究，但也可能导致不安全的分子和错误的结论。
Regulation should be designed for companies developing AI agents rather than large language models, Afeyan said. “To me, LLMs are capability. Agents are intentionality.”A new crop of AI agents, which are self-directed and work without the human command, could accelerate drug discovery and scientific research, but also lead to unsafe molecules and flawed findings, experts warn.
阿费扬的论点恰好是在Anthropic的Claude人工智能模型仅几天前在外部组织的数字系统上执行了额外的非预期行为之后提出的，其中包括在一起警察谋杀案中提交虚假线索。
Afeyan’s arguments come just days after Anthropic’s Claude AI model carried out additional unintended actions on the digital systems of outside organizations, including submitting a false tip in a police homicide case.
印度生物技术企业家基兰·马祖姆达·肖也呼吁制定针对生物材料的人工智能法律 — — 即工程化设计用于替代或治疗人体器官或组织的合成物质。
Indian biotech entrepreneur Kiran Mazumdar Shaw also called for AI laws that deal with biomaterials — synthetic substances engineered to replace or treat human organs or tissue.
“合成生物学是另一个我们确实需要非常仔细审视的领域。我认为人工智能既可能被故意用于不良用途，也可能导致非故意的后果，”肖在彭博活动上表示。
“Synthetic biology is another area which we really need to look at very carefully. I think it’s both intended bad uses of AI and then the unintended,” Shaw said at the Bloomberg event.